Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial

British Journal of Dermatology

Volumn 152, Issue 5, 2005, Pages 954-960

  Feldman, S R ^a   Gordon, K B ^b   Bala, M ^c   Evans, R ^c   Li, S ^c   Dooley, L T ^c   Guzzo, C ^c   Patel, K ^c   Menter, A ^d   Gottlieb, Alice B ^e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c CENTOCOR INC   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Infliximab; Monoclonal antibody; Quality of life; Randomized double blind placebo controlled trial

Indexed keywords

INFLIXIMAB; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EVALUATION; FEMALE; GENERAL CONDITION IMPROVEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM;

ADULT; ANTIBODIES, MONOCLONAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; PSORIASIS; PSYCHOMETRICS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 21044440425     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06510.x     Document Type: Article

References (21)

1. Gupta MA, Gupta AK. Psoriasis and sex: a study of moderately to severely affected patients. Int J Dermatol 1997; 36:259-62.
2. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol 1988; 118:195-201.
3. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96.
4. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med 1985; 20:425-9.
5. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989; 20:53-63.
6. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis, and psoriasis. Br J Dermatol 1998; 139:846-50.
7. Rapp SR, Feldman SR, Exum ML et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41:401-7.
8. Weiss SC, Kim ball AB, Liewehr DJ et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47:512-18.
9. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol Symp Proc 2004; 9:136-9.
10. Al-Suwaidan SN, Feldman SR. Clearance is not a realistic expectation of psoriasis treatment. J Am Acad Dermatol 2000; 42: 796-802.
11. Rapp SR, Exum ML, Reboussin DM et al. The physical, psychological and social impact of psoriasis. J Health Psychol 1997; 2: 525-37.
12. Chaudhari U, Romano P, Mulcahy LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357:1842-7.
13. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004; 51:534-42.
14. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19:210-16.
15. Conover WJ. Practical Nonparametric Statistics. New York: John Wiley & Sons, 1980.
16. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-4.
17. Choi J, Koo JYM. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49:S57-61.
18. Vensel E, Hilley T, Trent J et al. Sustained improvement of the quality of life of patients with psoriasis after hospitalization. J Am Acad Dermatol 2000; 43:858-60.
19. Kurwa HA, Finlay AY. Dermatology in-patient management greatly improves life quality. Br J Dermatol 1995; 133:575-8.
20. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol 2003; 4:131-9.
21. Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol 2004; 150:317-26.